Anavex Life Sciences Corp (AVXL)

[kspar1]

The Anavex platform strategy won me over 5+ years ago, and I'm still locked in.
Missling drives me nuts (too) -- poor communication/messaging skills (highlighted by pathetic web site)
and a control freak. Will never forget how he stepped on his CFO one CC to present their financial picture.

So why is he hellbent on the peer-reviewed publishing of 2-73 AD trial results?
Why put AVXL's fate in the hands of an editor and their publishing schedule (where Anavex presumably has no control)? Some thoughts...

1. use a 3rd party authority to backfill the uncertainty created by AVXL's disastrous CTAD reveal.
2. establish trust and validation, via legitimate source, to bless a completely new strategy to attack AD (and why it works),
3. create sufficient validation of the SOC supported by the 2-73 chemistry to give FDA an explanation (with some public pressure?) for blessing it.

Why would a publicly-traded company throw their fate to the wind, presuming they're in irons until the publication appears?
My wild guess is this peer-reviewed publication strategy was the result of internal condemnation (by Board, Advisors, and the poor guy who flew in from Australia to make the CTAD presentation). "Fix it CEO!"
I doubt a control freak would have proposed this.